

35 **KEY POINTS**

 \bullet Prolonged full KIR blockade leads to potentially deleterious effects on NK cells, $CD8^+$ T cells and vδ2⁺ $γδT$ cells
38 • Combined inhibitory effec Combined inhibitory effects of KIR blockade may have resulted in the impairment of 39 immunosurveillance associated with high rate of relapse 40 41 42 43 44 45 46

47 **ABSTRACT**

48 Lirilumab is a fully human monoclonal antibody designed to block killer inhibitory receptors 49 (KIR), which are major immune checkpoints involved in the regulation of NK cell-mediated 50 killing of HLA-I-expressing tumors. EFFIKIR is a multicenter randomized double-blind 3- 51 arm placebo-controlled phase II trial with lirilumab as single-agent as maintenance therapy of 52 elderly patients with AML in first complete remission (NCT01687387). Two dose schedules 53 led to either continuous or intermittent KIR occupancy. 153 patients were randomized and 54 152 patients were treated after 3+7 induction therapy. The median follow-up was 36.6 55 months. Lirilumab was well tolerated, with no significant hematological toxicity. The median 56 LFS were 17.6, 6.7 and 13.9 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, 57 respectively. An excess in early relapse led to early termination of treatment in the 1mg/kg 58 arm. Extensive analysis of immune cell fate following KIR blockade evidenced a decrease of 59 KIR⁺ NK cell absolute counts following KIR blockade, associated with a decrease of Bcl-2. 60 Lirilumab also bound antigen-experienced $CD8⁺$ T cells, and induced a transient decrease of 61 CD69 expression. Besides, lirilumab bound v $\delta 2^+$ γ δT cells with a high cytotoxic potential, 62 and induced a decrease of DNAM-1 and Bcl-2, the latter being associated with a decrease of 63 KIR⁺ γ ^oT cell, and with a drastic reduction of time to relapse. Overall, the potentially 64 deleterious effects on immune effectors may have resulted in the impairment of immune 65 surveillance associated with an unexpected high rate of early relapse in the group of patients 66 exposed to prolonged full KIR blockade.

67 **INTRODUCTION**

68 Killer cell Immunoglobulin-like Receptors (KIRs) are a class of major immune checkpoints 69 that negatively regulate Natural Killer (NK) cell anti-tumor activity.^{1,2} Inhibitory KIR, 70 KIR2DL and KIR3DL, display extracellular immunoglobulin-like domains conferring 71 specificity for HLA-C or HLA-A/B allotypes, respectively. Blockade of inhibitory NK 72 receptors has therefore the unique potential to enhance tumor cell killing without affecting 73 healthy tissues. NK cells are cytotoxic against malignant cells, including Acute Myeloid 74 Leukemia $(AML)^{1,3}$, and AML-induced NK cell alterations are associated with a poor 75 prognosis.^{4,5} KIR blockade by IPH2101, an anti-KIR monoclonal antibody, was found to be 76 generally safe and displayed signals of activity in hematologic malignancies.⁶ Lirilumab 77 (IPH2102/BMS-986015/BMS-986015-01) is a fully human IgG4 monoclonal antibody that 78 binds specifically and with high affinity to the main human inhibitory KIR, KIR2DL1 and 79 KIR2DL2/3. Lirilumab binding blocks the interaction of KIR2DL with HLA-C allotypes, 80 prevents inhibitory signals, and fosters activation NK cell activation. In a phase I study of 81 lirilumab in patients with hematological malignancies and solid tumors, we have shown that 82 as for IPH2101, lirilumab was safe and well tolerated.⁷

83 AML in older patients is associated with a dismal prognosis. With conventional intensive 84 chemotherapy, complete remission (CR) rates are comprised between 50% and 70% and the 85 relapse rate is high after remission, which results in median leukemia-free survival (LFS) of 86 about 12 months, median overall survival (OS) of 9 months and only 5-10% of patients are 87 Iong-term survivors. $8-12$ There is thus a need to develop effective maintenance strategies, and 88 immunotherapies targeting NK cell represent attractive approaches.

89

90 In our previous phase I study of lirilumab⁷, we observed that different pharmacodynamic 91 profiles where associated with lirilumab dose: a transient saturation with the lowest dose 92 versus a sustained full saturation with higher doses (0.015mg/kg versus 0.3mg/kg and above 93 in that study). Evidence has highlighted the importance of KIR receptors in NK cell 94 maturation and education^{13,14} and suggests that, in the clinic, transient KIR blockade might 95 allow both the optimal activation of NK cells and the education of new NK cells towards the 96 end of each treatment cycle when occupancy is reduced.

97 In order to evaluate the clinical efficacy of lirilumab and to determine the optimal dose-98 schedule, we designed a 3-arm phase II placebo-controlled study which compared the LFS of 99 elderly patients in first CR of AML treated with two dose-schedules of lirilumab or placebo.

100 A subset participated to a correlative study allowing for the double-blinded evaluation of the

101 functional and phenotypic changes induced by the 2 treatment arms compared to the control 102 group. The endpoints of the study were not met, and excess in early relapse led to early 103 termination of the study. Extensive analysis of the immune cell fate following KIR blockade 104 provides key elements to elucidate the potential mechanisms that led to this unexpected 105 excess of relapse despite inhibition of a major immune checkpoint.

106

107

108

109 **PATIENTS AND METHODS**

110 *Study design and treatment*

111 This is a prospective multicenter double-blinded phase II trial comparing two dose-schedules 112 of Lirilumab to a placebo control administered in the maintenance therapy of elderly patients 113 with AML in first CR following intensive chemotherapy. The study was conducted in 41 114 centers of the French ALFA and FILO cooperative groups.

115 Patients were randomized to one of the two treatment arms or placebo in a 1:1:1 ratio, with 116 minimization performed according to center, type of AML (primary versus secondary), 117 number of consolidation cycles (one versus two), and cytogenetics (high versus intermediate 118 risk). Lirilumab was administered at 0.1mg/kg every 12 weeks (arm A) or at 1mg/kg every 4 119 weeks (arm B) as a 1-hour IV infusion. Placebo (normal saline) was to be administered every 120 4 weeks as a 1-hour IV infusion in the placebo arm (arm C) and on weeks with no active 121 treatment in arm C, to ensure blinding. Patients were scheduled to receive 28-day cycles for 122 up to 24 months in the absence of intolerance or disease relapse. The study scheme is depicted 123 in Fig. 1. Lirilumab was provided by Innate Pharma (Marseille, France) as 5 mL vials 124 containing 10 mg/mL of lirilumab containing solution.

125 Study was approved by a national ethics committee (CPPRB) and registered at clinical 126 trial.gov (NCT01687387).

127

128 *Patients*

129 Main study eligibility criteria were: patients with de novo or secondary AML defined 130 according to World Health Organization 2008 criteria⁸, in first CR or CRi (according to the 131 revised recommendations of the International Working Group¹⁵) achieved after one or two 132 conventional induction chemotherapy and who had received one or two consolidation cycles. 133 Two different anthracycline-cytarabine containing induction and consolidation regimens 134 described in the Supplementary data section had been used as recommended by each

135 cooperative group. Induction chemotherapy had to have been administered within 6 months 136 before randomization and consolidation within 3 months following CR. Patient had to be non-137 eligible for an allogeneic hematopoietic stem cell transplantation (allo-HSCT), to be aged of 138 60 to 80 years, to have an Eastern Cooperative Oncology Group (ECOG) performance status 139 of 0 or 1; to have adequate renal and hepatic function. Patients with a history of auto-immune 140 disease, patients on steroids were not eligible. All patients gave written informed consent 141 prior to inclusion in the study.

142

143 *Efficacy and safety assessments*

144 Safety was to be assessed, using Common Terminology Criteria for Adverse Events (CTCAE) 145 version 4.03. A safety analysis was performed every 6 months for safety assessment by the 146 DSMB. The primary efficacy variable for this trial was LFS, defined as the time elapsed 147 between randomization and the occurrence of disease relapse or death from any cause. 148 Secondary efficacy variables were the time to relapse (TTR), OS. TTR was defined as the 149 time elapsed between randomization and the occurrence of disease relapse; OS was the time 150 between randomization and death from any cause. Patients who had not progressed or died by 151 the time of the final analyses, were censored as of the date of last contact for calculation of 152 LFS, OS and TTR. Assessment of disease relapse was performed every 4 weeks during the 153 treatment and during follow-up periods. Relapse was defined according to IWG criteria.¹⁵

154

155 *Statistical analysis*

156 The planned sample size for the study comprised 150 patients (i.e., 50 patients were to be 157 randomized to each treatment arm). This sample size was estimated in order to demonstrate a 158 hazard ratio (HR) for LFS of 0.6 in favor of maintenance therapy with an 80% power for a 159 one-sided log-rank test at an overall alpha level of 5%. The final sample size consisted of 169 160 screened patients, 153 randomized patients, and 152 treated patients. All efficacy analyses 161 were performed using data from the Intention-to-treat (ITT) Population, which consisted of all 162 subjects who received at least one dose of study medication. The Safety Population used for 163 the safety analyses consisted of all patients who received at least one dose of lirilumab.

164 Following a DSMB meeting held on 10 March 2015, a unanimous recommendation was made 165 to stop further treatment for ongoing patients treated with lirilumab 1mg/kg due to an 166 apparent excess of early relapses compared with the two other groups. It was decided to keep 167 the same assumptions regarding the number of LFS events to be observed in these two

168 groups, i.e. 69 LFS events. Consequently, the primary efficacy analysis was performed on 169 these two groups, with the alpha level decreased to 2.5% and the power to 55%.

170 LFS was analyzed using the log-rank test stratified by the following stratification factors, as 171 recorded in the randomization file: primary versus secondary AML, and cytogenetics (high 172 versus intermediate risk). The stratification factor "number of consolidation cycles (1 versus 173 2)" was not used in the log-rank test because there were too few patients in some 174 combinations of strata and the log-rank test failed in this situation.

175

176 *Mass cytometry*

177 PBMC were collected at C1D1H0, C1D8, C4D1, C7D1 and end of study (EOS), and 178 cryopreserved in 10% DMSO. Forty-three patients participated to this correlative study (12 in 179 arm 0.1mg/kg, 16 in arm 1.0mg/kg and 15 in the control arm. A total of 141 samples were 180 analyzed among which 39 were collected at C1D1H0, 35 at C1D8, 26 at C4D1, 18 at C7D1, 181 and 23 at EOS. PBMCs were processed as previously described.^{5,16} The detailed protocol is 182 provided in appendix. Lymphocytes were exported for further analysis using opt- $SNE¹⁷$. 183 Lirilumab-bound cells were identified using a metal-conjugated anti-IgG4 antibody. 184

185 186

187 **RESULTS**

188 **Patient characteristics**

189 Between November 2012 and July 2014, 169 patients were screened, 153 were randomized, 190 and 152 were treated (Table 1). One patient was not treated in the lirilumab 0.1mg/kg arm, 191 due to consent withdrawal before treatment initiation. The final numbers of patients were 50 192 in the lirilumab 0.1mg/kg arm, 51 in the lirilumab 1mg/kg arm, and 51 in the placebo arm 193 (Fig. 1A). No significant imbalances were seen across treatment arms. Median age was 70 194 years. One fourth of patients had a favorable European LeukemiaNet (ELN) 2010 genetic 195 subtype of AML. The median time since AML diagnosis was 4.8 month and 81% of patients 196 had received two consolidation cycles prior to inclusion.

197

198 **Treatment**

199 Following a Data and Safety Monitoring Board (DSMB) recommendation on 10 March 2015, 200 the decision was made to stop further treatment for ongoing patients treated with lirilumab

201 1mg/kg due to an apparent excess of early relapses compared with the two other groups. At

202 that time, recruitment had already been completed. As a result, exposure was greater in the 203 lirilumab 0.1mg/kg arm (median number of cycles of 16) and in the placebo arm (median 204 number of cycles of 11) as compared to the lirilumab 1mg/kg arm (median number of cycles 205 of 8).

206 Relapse (62.7%) was the main reason for discontinuation (52.9% from the 0.1mg/kg arm, 207 72.5% from the 1mg/kg arm, and 62.7% from the placebo arm), followed by adverse events 208 (AEs) (10.5%), withdrawal of consent, investigator's decision, and sponsor's decision (1.3% 209 each) (Fig. S1).

210

211 **Efficacy results**

212 Efficacy analysis concerned only the comparison between lirilumab 0.1mg/kg versus placebo 213 (Fig. 1). The study did not meet its primary endpoint, as no significant difference between 214 lirilumab 0.1mg/kg and placebo was seen (stratified LFS Hazard ratio (HR): 0.98 (95% 215 confidence interval [CI], 0.61 to 1.56, p=0.936). The median LFS were 17.6, 6.7 and 13.9 216 months in the 0.1mg/kg arm, 1mg/kg arm and placebo arm, respectively. Regarding the 217 comparison between lirilumab 1mg/kg and placebo, no statistically significant difference was 218 observed, but LFS in the lirilumab 1mg/kg arm was inferior to that in the placebo arm 219 (median LFS of 6.7 months, HR 0.95; 95% CI, 0.59 to 1.53; p=0.177) (Fig. 1B).

220 With regard to secondary efficacy endpoints, no significant differences were found in any of 221 the comparisons which TTR times, median OS (31.3, 20.2 and 41.6 months in the 0.1mg/kg 222 arm, 1 mg/kg arm and placebo arm, respectively, $p=0.602$ and 0.058) (Fig. 1C).

223 No prognostic factor for LFS for the comparison between lirilumab 0.1mg/kg and placebo 224 was seen. For the comparison of lirilumab 1mg/kg with placebo, the type of induction therapy 225 (idarubicin vs daunorubicin) and the number of platelets at the time of inclusion (<100 vs 226 \geq 100 x10⁹/L) were identified in the Cox model as independent prognostic factors for LFS 227 (HR=1.35 and 4.14, respectively). Results are summarized as Forest Plots displayed in Fig. 228 S2A and S2B.

229 As previously mentioned, an excess in early relapse was observed and justified early 230 termination of treatment in the 1mg/kg arm. Although LFS was not statistically different 231 between arms, curves clearly show an early drop in LFS in this arm as compared to the 2 232 others.

- 233
- 234 **Safety**

235 Overall, 91.4% of patients had at least one treatment-emergent AE. The event rates (i.e. the

- 236 number of patients with AEs divided by the total drug exposure in months), was lower in the
- 237 lirilumab 0.1mg/kg arm than in the lirilumab 1mg/kg and the placebo arms. The most frequent
- 238 AEs are presented in Table 2. Infusion-related reactions were the most frequent, did not reach
- 239 a grade 4, while grade 3 reactions frequency was nearly identical in the three arms.
- 240 No significant hematological toxicity was seen in the 3 arms. Eighteen malignant tumors were 241 reported in 14 patients. 75% of patients were in the lirilumab 0.1mg/kg arm. There were 3
- 242 basal-cell carcinoma, and the other six neoplasms had each a maximum of one case. In the
-
- 243 other two arms combined, there were 3 myeloid malignancies, 6 solid tumors (including 2 244 basal cell carcinomas).
- 245 A total of 81 deaths were reported during the study: 26 in the lirilumab 0.1mg/kg arm, 32 in 246 the lirilumab 1mg/kg arm, and 23 in the placebo arm. Nearly 85% of such deaths were 247 attributed to disease progression across the three arms.
- 248

249 **Pharmacokinetics and pharmacodynamics**

250 PK-PD sampling was performed for the first 60 randomized patients. Intermittent full KIR 251 occupancy was observed with the dose of 0.1mg/kg every 3 months, with full KIR occupancy 252 lasting 7 days to 1 month for the majority of the patients. Long-term full KIR occupancy was 253 observed at the dose of 1mg/kg every 4 weeks (Fig. S3).

254

255 **Immune modifications during treatment**

256 Lirilumab was not immunogenic with 15 patients presenting Human Anti-Human Antibodies, 257 all with low titers. Of note, 9 out of the 15 positive patients tested positive at baseline and 258 5/15 patients were in the placebo arm (data not shown). Lirilumab-induced immune 259 modifications were then extensively analyzed by mass cytometry. For these experiments, we 260 used a metal-conjugated anti-IgG4 antibody in order to specifically identify lirilumab-bound 261 immune cells (Fig. 2A). As expected, based on prior *in vitro* studies¹⁸, lirilumab bound KIR-262 expressing immune populations, including NK cells, Vγ9Vδ2⁺ γδT cells, CD8⁺ T cells, and to 263 a lesser extent CD4⁺ T cells (Fig. 2B-C). Eight days after lirilumab injection, 26.0% and 264 25.8% of NK cells had bound lirilumab in the lirilumab 0.1 and lirilumab 1.0 arms, 265 respectively (Fig. 2C). The frequency of lirilumab-bound Vγ9V $\delta 2^+$ γ δT cells was 12.3% and 266 8.2% in the lirilumab 0.1 and lirilumab 1.0 arms, respectively. The mean frequency of 267 lirilumab-bound cells was below 6% for $CD8^+$ T cells, and below 1% for $CD4^+$ T cells in both 268 arms. The frequency of lirilumab-bound immune cells was significantly decreased by C4D1

269 in the lirilumab 0.1 arm, while maintained in the lirilumab 1.0 arm until the end of study (Fig.

- 270 2C).
- 271

272 The impact of lirilumab binding on NK cells was further characterized using dimensionality 273 reduction analysis. Since one of the main hypotheses retained to explain the lack of clinical 274 benefit of anti-KIR therapy in multiple myeloma was the potential interference with NK cell 275 education and development^{19,20}, we first focused on NK cell maturation profiles. Lirilumab 276 did not induce any phenotypical shift, even after prolonged administration, except a slight 277 decrease of CD56^{bright} NK cells at end of study (Fig. 3A and Fig. S4A). Besides, we observed 278 a transient decrease of the cluster of $KIR⁺ NK$ cells in the lirilumab 0.1 arm, and a durable 279 decrease of this population in the lirilumab 1.0 arm (Fig. S4B). Analysis of absolute counts of 280 KIR⁺ NK cells in both arms at C1D8 evidenced a weak to drastic decrease in 17 out of 20 281 patients treated with lirilumab compared with baseline, while this decrease was weak and 282 limited to 3 out of 12 patients in the placebo arm (Fig. 3B), confirming prior observations in 283 multiple myeloma¹⁹. This decrease of $KIR⁺ NK$ cells was concomitant with a transient 284 decrease at C1D8 of the anti-apoptotic protein Bcl-2 in the lirilumab 1.0 arm, a critical protein 285 NK cell survival.²¹ This decrease affected all the populations of NK cells, independently of 286 lirilumab binding (Fig. 3C), suggesting an indirect mechanism involved in the loss of Bcl-2 287 consecutive to KIR blockade. Although not significant, a similar trend was also observed in 288 the lirilumab 0.1 arm (Fig. 3C).

289

290 Lirilumab binding on CDS^+ T cells did not induce any phenotypical shift (Fig. 4A), and did 291 not impact T cell maturation profiles (data not shown). Lirilumab spared naive $(CD27⁺)$ $CCR7^+$ CD45RA⁺ CD28⁺), central memory (CD27⁺ CCR7⁺ CD45RA⁻), and effector memory 293 (CD27 CCR7 CD45RA) CD8⁺ T cells, and preferentially bound antigen-experienced CD8⁺ 294 T cells with a terminally differentiated profile (CD27 CCR7 CD45RA⁺ CD28). Most 295 Iirilumab-bound CDS^+ T cells also expressed $CDS6$ and $CDI6$, a phenotypic hallmark of T 296 cells with NK cell-like functions, and enhanced TCR-independent/CD16-dependent 297 degranulation potential.^{22,23} These cells also expressed the long-term immunological memory 298 marker CD57²⁴ (Fig. 4A). Upon lirilumab binding, we observed a decreased expression of the 299 activation marker CD69, a key regulator of tumor-specific CD8⁺ T cells differentiation.²⁵ This 300 decrease was significant in arm 1.0 at late time points (C7D1), specifically affected lirilumab-301 bound CDS^+ T cells, and spared lirilumab-free CDS^+ T cells (Fig. 4B). We further analyzed 302 the effect of lirilumab binding at early time points on paired samples between C1D8 and

303 C4D1. Lirilumab was found to induce heterogeneous inter-individual responses after binding 304 to $CD8⁺$ T cells. In 4 out of 8 patients, lirilumab induced up-regulation of the key immune 305 checkpoints CTLA-4, PD-1, and BTLA, which was likely the consequence of a prior 306 activation, as evidenced by higher expression of CD25 (IL-2R), CD28, as well as the 307 inducible co-stimulatory receptors OX40 and 4-1BB (Fig. 4C). In these patients, we also 308 observed an increase of exhausted $CDS⁺ T$ cells characterized by co-expression of PD-1 and 309 TIGIT, two co-inhibitory receptors increased upon T cell activation.²⁶

- 310 We next focused on v $\delta 2^+$ $\gamma \delta T$ cells, a key population of anti-tumor cells with particular 311 relevance in the context of tumors with low mutational burden and high plasticity in MHC-I 312 expression such as AML.²⁷⁻³⁰ Lirilumab mainly bound vδ2⁺ γδT cells with a high cytotoxic 313 potential $(CD8^+ \text{ } CD56^+ \text{ } CD57^+ \text{ } CD16^+)$ (Fig. 5A). The number of anti-IgG4⁺ $\gamma \delta T$ cells was 314 insufficient in most patients from arm 0.1 and prevented performing reliable measurements in 315 this group. Upon administration, lirilumab induced a transient decrease of DNAM-1 at C7D1 316 in arm 1.0, a critical receptor involved in cytotoxicity (Fig. 5B). Besides, we observed a 317 decrease of absolute counts of anti-IgG4⁺ $v\delta2^+$ $\gamma\delta T$ cells between C1D8 et C4D1 in arm 1.0 318 (Fig. 5C). As for NK cells, depletion of lirilumab-bound v $\delta 2^+$ $\gamma \delta T$ cells was associated with a 319 transient decrease of Bcl-2 at C1D8, affecting v $\delta 2^+ \gamma \delta T$ cells independent of lirilumab binding 320 (Fig. 5B). The effect of lirilumab on Bcl-2 expression was not correlated with treatment 321 schedules, and some patients in arm 0.1 displayed marked decrease of Bcl-2 despite reduced 322 lirilumab dosing. We therefore performed a pooled analysis of both treatment arms according 323 to Bcl-2 expression among patients that relapsed before the end of study. Patients with LFS 324 above the median maintained a high frequency of Bcl- 2^+ v $\delta 2^+$ $\gamma \delta T$ cells at C4D1, in contrast 325 to patients with LFS below the median (Fig. 5D). Consistently, the frequency of Bcl- 2^+ v $\delta 2^+$ 326 γ δ T cells was decreased in all patients with LFS<3mo, while the frequency of Bcl-2⁺ ν δ 2⁺ 327 γδT cells was increased or stable in 8 out of 11 patients with LFS >3 mo (Fig. 5E). In line, 328 patients with decreased Bcl-2 expression displayed shorter time to relapse than patients with 329 stable or increased Bcl-2 expression at C1D8 (Fig. 5E). The apparent recovery of Bcl-2 by 330 C4D1 (Fig. 5B) might therefore be artefactual and potentially biased by the fact that most 331 patients with loss of Bcl-2 between C1D0 and C1D8 display LFS<3mo. Taken together, these 332 results highlight a potential link between loss of Bcl-2 in v $\delta 2^+$ $\gamma \delta T$ cells consecutive to KIR 333 blockade and early relapse in patients treated with lirilumab. 334
	- 11

335 **DISCUSSION**

336 The current randomized phase II trial failed to meet its primary objective of demonstrating the 337 efficacy of lirilumab given as maintenance therapy in elderly patients in first CR from AML. 338 The primary endpoint, LFS, did not differ significantly between either of the lirilumab arms 339 and placebo arm, and there were no statistically significant differences in the secondary 340 efficacy endpoints of TTR and OS. However, the lirilumab 0.1mg/kg arm was associated with 341 a non-significant trend toward a higher LFS as compared to the placebo arm (17.6 versus 13.9 342 months) while an inverse trend was seen in the lirilumab 1mg/kg arm. The latter was stopped 343 early upon a DSMB decision due to the observation of a high rate of early relapse, which 344 translated into a shorter median OS ($p=0.058$).

345 We were not able to identify confounding factors which may explain the differences between 346 the 2 lirilumab arms. These include clinical and biological classical AML prognostic factors 347 such as the number of induction courses to achieve a CR, cytogenetics, and ELN genetic risk 348 classification. However, important parameters such as the level of minimal residual disease at 349 inclusion could not be assessed. Doses of 0.1mg/kg of lirilumab were associated with full but 350 transient KIR saturation on NK cells while 1mg/kg dose every 4 weeks led to continuous 351 saturation. However, it must be noted that substantial inter-patient variability was observed 352 and that some patients in the low dose arm actually achieved continuous full KIR saturation.

353

354 In order to decipher the mechanism involved in the excess of early relapse observed, we 355 developed mass cytometry panels to track lirilumab-bound cells during the course of 356 treatment, and dissect its impact on immune cell fate. We evidenced a decrease of $KIR⁺ NK$ 357 cell absolute counts following KIR blockade, confirming the results of the phase II trial 358 assessing lirilumab in multiple myeloma.¹⁹ One hypothesis retained to explain the lack of 359 clinical benefit of anti-KIR therapy in this setting was the potential interference with NK cell 360 maturation homeostasis²⁰, the latter being critical in AML as recently evidenced by our 361 group.⁵ We failed to evidence maturation defects following lirilumab administration. Rather, 362 we evidenced a decrease of Bcl-2, a downstream target of IL-15 signaling, involved in 363 mitochondrial apoptosis, autophagy and senescence.^{31–33} The ability of lirilumab to target T 364 cells was notable, confirming prior pre-clinical observations.¹⁸ Lirilumab preferentially bound 365 antigen-experienced $CD8^+$ T cells, leading to a transient decreased activation. The impact of 366 lirilumab on the vδ2⁺ γδT cell compartment was marked by a decreased expression of 367 DNAM-1 and Bcl-2, the latter being associated with a decrease of the absolute counts of KIR⁺ 368 γ δT cell, echoing previous work showing that inhibitory KIR (iKIR) expression on human T

369 cells is associated with higher levels of Bcl-2, and that blocking the iKIR-HLA interaction 370 significantly decreased the count of live T cells^{34,35}. Similar observations have also been 371 reported in the context of renal cell carcinoma: blocking the interaction of KIR/HLA-Cw4 372 resulted in the restoration of tumor-induced cell death following activation by interfering with 373 two proximal events of Fas signaling pathway, a sustained c-FLIP-L induction and a decrease 374 in caspase 8 activity.³⁶ In line, recent work showed that KIR/HLA interactions extend lifespan 375 of human $CD8⁺$ T cells.³⁷ Although no confirmation of such mechanisms has been reported in 376γ δ T cells, we can speculate that similar mechanisms triggering cell death are engaged 377 following KIR blockade on these cells, the latter point requiring dedicated mechanistic 378 studies. Finally, this loss of Bcl-2 was associated with a drastic reduction of time to relapse. Given the strong correlation between Bcl-2 expression by $\gamma \delta T$ cells, CD8⁺ T cells and NK 380 cells, we cannot exclude a cumulative negative effect of Bcl-2 down-regulation on these three 381 main anti-leukemic populations. However, these results extend the list of arguments in favor 382 of the central role of γδT cells in the control of leukemic blast proliferation.

383 In conclusion, this study failed to demonstrate that lirilumab can prolong CR duration. In 384 addition, we observed potentially deleterious effects on various immune effectors. These 385 effects - which have not been previously reported - suggest that combined inhibitory effects 386 may have resulted in the impairment of immune surveillance associated with an unexpected 387 high rate of early relapse in the group of patients exposed to prolonged full KIR blockade. 388 The results also confirm the importance of $\gamma \delta T$ cells in the control of AML cells opening new 389 avenues for future immunotherapeutic strategies. $38,39$

390 Overall, this study underlies the need to closely monitor the consequences of therapeutic 391 monoclonal antibodies binding on immune populations that appear minor in absolute number, 392 especially when these cells play a key role in tumor clearance. It also warns against the 393 possibility that immune interventions be associated with narrow therapeutic windows.

394

395

396 **Competing interests**

397 P.A. is an employee and a shareholder of Innate Pharma. D.O. is the co-founder and a 398 shareholder of Imcheck therapeutics, Emergence therapeutics, and Alderaan Biotech.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.23.24312477;](https://doi.org/10.1101/2024.08.23.24312477) this version posted August 23, 2024. The copyright holder for this preprint

399 **Author contribution statement**

- 400 N.V. and H.D. designed the research. N.V., H.D., P.A,. A.S.C., A.T., N.D., and D.O. designed 401 the ancillary study. N.V. and A.S.C analyzed the data and drafted the article. N.V., C.R., L.G.,
- 402 B.L., C.E.B, C.P., J.P.L, S.L., E.R., E.R., X.T., Y.H., C.B., B.C., P.R., J.V.M, G.G., J.H.B.,
- 403 M.O.U., M.H., C.P., N.I., and H.D. recruited patients, conducted patient follow-up, and
- 404 collected clinical data. A.B.A., N.B. and M.S.R. designed the mass cytometry panels and
- 405 performed the mass cytometry experiments. All authors revised and approved the manuscript.
- 407 **REFERENCES**
- 408
409

406

- 409 1. Caligiuri, M. A. Human natural killer cells. *Blood* **112**, 461–469 (2008).
- 410 2. Bryceson, Y. T., March, M. E., Ljunggren, H.-G. & Long, E. O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* 107, 159–166 (2006). 411 cells for the activation of natural cytotoxicity and cytokine secretion. *Blood* **107**, 159–166 (2006).
- 412 3. Caligiuri, M. A., Velardi, A., Scheinberg, D. A. & Borrello, I. M. Immunotherapeutic approaches for hematologic malignancies. *Hematology Am Soc Hematol Educ Program* 337–353 (2004) 413 hematologic malignancies. *Hematology Am Soc Hematol Educ Program* 337–353 (2004)
- 414 doi:10.1182/asheducation-2004.1.337.
415 4. Fauriat. C. *et al.* Deficient expression of 415 4. Fauriat, C. *et al.* Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during 416 leukemia treatment and impact of leukemia cells in NCR dull phenotype induction. *Blood* 109, 323–330 416 leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood* **109**, 323–330
- 417 (2007).
418 5. Chretie 418 5. Chretien, A.-S. *et al.* High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a 419 subgroup with adverse clinical outcome. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2020459118 (2021).
- 420 6. Vey, N. *et al.* A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. *Blood* 421 **120**, 4317–4323 (2012).
422 7. Vey, N. *et al.* A phase 1
- 422 7. Vey, N. *et al.* A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody 423 KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget* 9, 17675–1768 423 KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. *Oncotarget* **9**, 17675–17688
- 424 (2018).
425 8. Vardim 425 8. Vardiman, J. W. *et al.* The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 114, 937–51 (2009). 426 neoplasms and acute leukemia: rationale and important changes. *Blood* **114**, 937–51 (2009).
- 427 9. Brune, M. Improved leukemia-free survival after postconsolidation immunotherapy with histamine
428 dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. 428 dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. *Blood*
- 429 **108**, 88–96 (2006). 430 10. Gardin, C. *et al.* Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia 431 remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia
432 French Association (ALFA) 9803 trial. *Blood* **109**, 5129–5135 (2007).
- 432 French Association (ALFA) 9803 trial. *Blood* **109**, 5129–5135 (2007). 433 11. Büchner, T. *et al.* Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia:
434 A Study by the German Acute Myeloid Leukemia Cooperative Group. *JCO* 27, 61–69 (2009).
- 434 A Study by the German Acute Myeloid Leukemia Cooperative Group. *JCO* **27**, 61–69 (2009). 435 12. Löwenberg, B. *et al.* Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or 436 more: results of a multicenter phase 3 study. *Blood* **115**, 2586–2591 (2010).
437 13. Anfossi. N. *et al.* Human NK cell education by inhibitory receptors for MH
- 437 13. Anfossi, N. *et al.* Human NK cell education by inhibitory receptors for MHC class I. *Immunity* **25**, 331–42 438 (2006).
439 14. Fauriat.
- 439 14. Fauriat, C. *et al.* Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. *J Immunol* 181, 6010–9 (2008).
- 440 homozygous for the group A KIR haplotype. *J Immunol* **181**, 6010–9 (2008). 441 15. Cheson, B. D. *et al.* Revised recommendations of the International Working Group for Diagnosis, 442 Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials
443 in Acute Myeloid Leukemia. *Journal of clinical oncology* \Box : *official journal of the American Society of* 443 in Acute Myeloid Leukemia. *Journal of clinical oncology: official journal of the American Society of*
- 444 *Clinical Oncology* **21**, 4642–9 (2003). 445 16. Ben Amara, A. *et al.* High-throughput mass cytometry staining for deep phenotyping of human natural killer 446 cells. *STAR Protoc* **3**, 101768 (2022).
- 447 17. Belkina, A. C. *et al.* Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets. Nat Commun **10**, 5415 (2019). 448 improve visualization and analysis of large datasets. *Nat Commun* **10**, 5415 (2019).
- 449 18. Romagné, F. *et al.* Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic
450 antibody that augments natural killer–mediated killing of tumor cells. *Blood* 114, 2667–2677 (2009). 450 antibody that augments natural killer–mediated killing of tumor cells. *Blood* **114**, 2667–2677 (2009).
- 451 19. Carlsten, M. *et al.* Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces
452 Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. *Clinical Cancer Researe* 452 Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. *Clinical Cancer Research* **22**,
- 453 5211–5222 (2016).
454 20. Sanchez-Correa, B. 454 20. Sanchez-Correa, B. *et al.* Modulation of NK cells with checkpoint inhibitors in the context of cancer 455 immunotherapy. *Cancer Immunol Immunother* **68**, 861–870 (2019).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.23.24312477;](https://doi.org/10.1101/2024.08.23.24312477) this version posted August 23, 2024. The copyright holder for this preprint

- 456 21. Malamut, G. *et al.* IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a
457 botential new target in celiac disease-associated inflammation and lymphomagenesis. *J Clin Invest* 12 457 potential new target in celiac disease-associated inflammation and lymphomagenesis. *J Clin Invest* **120**,
- 458 2131–2143 (2010).
459 22. Björkström, N. K. e 459 22. Björkström, N. K. *et al.* Elevated Numbers of FcγRIIIA+ (CD16+) Effector CD8 T Cells with NK Cell-Like
- 460 Function in Chronic Hepatitis C Virus Infection. *The Journal of Immunology* **181**, 4219–4228 (2008). 461 23. Georg, P. *et al.* Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell* **185**,
- 462 493-512.e25 (2022).
463 24. Ahmed, R. *et al.* CD. 463 24. Ahmed, R. *et al.* CD57+ Memory T Cells Proliferate In Vivo. *Cell Rep* **33**, 108501 (2020).
- 464 25. Koyama-Nasu, R. *et al.* CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes. 465 *Cancer Immunol Res* **11**, 1085–1099 (2023).
- 26. Banta, K. L. *et al.* Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-
467 blockade to optimize anti-tumor CD8+ T cell responses. *Immunity* 55, 512-526.e9 (2022). 467 blockade to optimize anti-tumor CD8+ T cell responses. *Immunity* **55**, 512-526.e9 (2022).
- 468 27. Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. *Nat Rev Clin Oncol* **20**, 178–191 (2023). 469 immunotherapy. *Nat Rev Clin Oncol* **20**, 178–191 (2023).
- 470 28. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. *Science* **348**, 69–74 (2015).
- 471 29. Christopher, M. J. *et al.* Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. *N Engl J* 472 *Med* **379**, 2330–2341 (2018).
- 473 30. Toffalori, C. *et al.* Immune signature drives leukemia escape and relapse after hematopoietic cell 474 transplantation. *Nat Med* **25**, 603–611 (2019).
- 475 31. Chong, S. J. F. *et al.* Noncanonical Cell Fate Regulation by Bcl-2 Proteins. *Trends Cell Biol* **30**, 537–555 476 (2020).
477 32.Czabota
- 477 32. Czabotar, P. E. & Garcia-Saez, A. J. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. *Nat* 478 *Rev Mol Cell Biol* **24**, 732–748 (2023).
- 479 33. Ma, S., Caligiuri, M. A. & Yu, J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer
480 immunotherapy. *Trends Immunol* 43, 833–847 (2022). 480 immunotherapy. *Trends Immunol* **43**, 833–847 (2022).
- 34. Boelen, L. *et al.* Inhibitory killer cell immunoglobulin-like receptors strengthen CD8⁺ T cell–mediated control of HIV-1, HCV, and HTLV-1. *Sci. Immunol*. **3.** eaao2892 (2018). 482 control of HIV-1, HCV, and HTLV-1. *Sci. Immunol.* **3**, eaao2892 (2018).
- 483 35. Young, N. T., Uhrberg, M., Phillips, J. H., Lanier, L. L. & Parham, P. Differential Expression of Leukocyte 484 Receptor Complex-Encoded Ig-Like Receptors Correlates with the Transition from Effector to Memory CTL.
485 The Journal of Immunology 166, 3933–3941 (2001). 485 *The Journal of Immunology* **166**, 3933–3941 (2001).
- 486 36. Gati, A. *et al.* CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-
487 induced cell death by interfering with Fas signaling. *Cancer Res* 63, 7475–7482 (2003). 487 induced cell death by interfering with Fas signaling. *Cancer Res* **63**, 7475–7482 (2003).
- 488 37. Zhang, Y. *et al.* KIR-HLA interactions extend human CD8+ T cell lifespan in vivo. *Journal of Clinical* 489 *Investigation* **133**, e169496 (2023).
- 490 38. Cano, C. E. *et al.* BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. *Cell Rep* **36**, 109359 (2021). 491 cells. *Cell Rep* **36**, 109359 (2021).
- 492 39. De Gassart, A. *et al.* Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci Transl Med 13, eabj0835 (2021). 493 cell-mediated antitumor immune response. *Sci Transl Med* **13**, eabj0835 (2021).
- 494

497 Table 1: Patient characteristics

498

499

500 Table 2: Adverse events occurring in >10% of patients

501

502

503

504

505 **Figure legends**

506

507 **Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1**

508 **mg/kg or placebo.** A: Study design. B: Primary endpoint: Leukemia-Free Survival. C:

509 Secondary endpoint : Overall Survival.

510

511 **Figure 2: Distribution of lirilumab binding on immune populations.** PBMC from patients 512 in arm 0.1 mg/kg (N=12), arm 1.0 mg/kg (N=16) and control arm (N=15) were collected at 513 C1D1H0, C1D8, C4D1, C7D1 and EOS and phenotyped by mass cytometry. A: Lirilumab-514 bound cells were identified using metal-conjugated an $α$ -IgG4 antibody. B: Consensus files 515 were generated using fixed number of αIgG4+ cells from each .fcs file, and projected on a t-516 SNE map. C: Frequency of αIgG4+ cells by treatment arm and by time point of blood 517 collection among CD4+ T cells, CD8+ T cells, V δ 2+ γ δ T cells, and NK cells. Data were 518 analyzed using a Kruskal-Wallis test followed by a Dunn's post test. $*P < 0.05$; $*P < 0.01$; 519 ****P* < 0.001; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: 520 cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

521

522 **Figure 3 : Impact of lirilumab on NK cells.** A: Total peripheral NK cells were manually 523 pregated and exported for t-SNE analysis. Consensus files of αIgG4+ NK cells were 524 generated with fixed number of cells for each treatment arm at each time point in order to 525 obtain a representative and balanced view of all patient groups. Consensus files were then 526 projected on t-SNE plots of total NK cells. B: Variations of absolute counts of KIR+ NK cells 527 between baseline and C1D8. C: Bcl-2 expression by treatment arm and by time point of blood 528 collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on 529 KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on αIgG4+ NK cells for arms A 530 and B. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. For 531 multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's 532 post test, and presented as interquartile ranges, median, and whiskers from minimum to 533 maximum. $*P < 0.05$; $**P < 0.01$; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: 534 cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; PCB: placebo.

535

536 **Figure 4: Impact of lirilumab on CD8+ T cells.** A: Total peripheral CD8+ T cells were 537 manually pregated and exported for t-SNE analysis. Consensus files of αIgG4+ CD8+ T cells 538 were generated with fixed number cells for each treatment arm at each time point. Consensus

539 files were then projected on t-SNE plots of total CD8+ T cells. B: CD69 expression by 540 treatment arm and by time point of blood collection. C: Variations of T cell triggering 541 receptors, immune checkpoints and activation markers expression between C1D8 and C4D1. 542 Paired samples from patients included in 1.0 arm were analyzed using hierarchical clustering. 543 For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a 544 Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum 545 to maximum. $*P < 0.05$; $*P < 0.01$; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; 546 C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

547

⁵⁴⁸**Figure 5 : Impact of lirilumab on v**δ**2+** γδ**T cells.** A: Total peripheral vδ2+ γδT cells were 549 manually pregated and exported for t-SNE analysis. Consensus files of $\alpha I gG4 + v\delta 2 + \gamma \delta T$ 550 cells were generated with fixed number cells for each treatment arm at each time point. 551 Consensus files were then projected on t-SNE plots of total v $\delta 2 + \gamma \delta T$ cells. B: DNAM-1 and 552 Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-553 gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8 554 to EOS were pre-gated on αIgG4+ NK cells for arms A and B. C: variations of absolute 555 counts of αIgG4+ vδ2+ γδT cells during the cours of treatment. D: Bcl-2 expression at C1D8 556 according to LFS. E: Variations of Bcl-2 expression between C1D1H0 and C1D8 according 557 to LFS (upper and middle panels). Time to relapse according to Bcl-2 variations between 558 C1D1H0 and C1D8 (lower panel). For multiple comparisons, data were analyzed using a 559 Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, 560 median, and whiskers from minimum to maximum. Paired samples were analyzed using a 561 Wilcoxon matched-pairs signed rank test. Comparison between two groups were performed 562 using a Mann–Whitney *U* test. **P* < 0.05; ***P* < 0.01; ns, nonsignificant. C1D1H0: cycle 1 563 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of 564 study; LFS: leukemia-free survival; PCB: placebo.

- 565
- 566
- 567

Figure 1: Clinical outcome in patients treated with lirilumab 1.0 mg/kg, lirilumab 0.1 mg/kg or placebo. A: Study design. B: Primary endpoint: Leukemia-Free Survival. C: Secondary endpoint : Overall Survival.

Placebo Q4W 0.1 mg/kg Q12W 1 mg/kg Q4W

C

Figure 2: Distribution of lirilumab binding on immune populations. PBMC from patients in arm 0.1 mg/kg (N=12), arm 1.0 mg/kg (N=16) and control arm (N=15) were collected at C1D1H0, C1D8, C4D1, C7D1 and EOS and phenotyped by mass cytometry. A: Lirilumab-bound cells were identified using metal-conjugated an α-IgG4 antibody. B: Consensus files were generated using fixed number of αIgG4+ cells from each .fcs file, and projected on a t-SNE map. C: Frequency of αIgG4+ cells by treatment arm and by time point of blood collection among CD4+ T cells, CD8+ T cells, Vδ2+ γδT cells, and NK cells. Data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

C

Figure 3 : Impact of lirilumab on NK cells. A: Total peripheral NK cells were manually pregated and exported for t-SNE analysis. Consensus files of α IgG4+ NK cells were generated with fixed number of cells for each treatment arm at each time point in order to obtain a representative and balanced view of all patient groups. Consensus files were then projected on t-SNE plots of total NK cells. B: Variations of absolute counts of KIR+ NK cells between baseline and C1D8. C: Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on αIgG4+ NK cells for arms A and B. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. *P < 0.05; **P < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; PCB: placebo.

0.1 mg/kg

1mg/kg

5

CD69+ / **algG4+ CD8 T cells**

20

20

4

20

4

20

20

20

20

20

20

20

% CD69+ / α lgG4+ CD8 T cells

100

5

% CD69+ / α lgG4+ CD8 T cells

100

CD69+ / αIgG4+ CD8 T cells

ns

ns

ns

ns

ns

C₄₀ C_1 ⁰ C_2 ⁰

CIVDB

ns

ns

*

ns

**

ns

C₁₀ C_1 ⁰ C_2 ⁶

C108

ns

% CD69+ / algG4- CD8 T cells

C

Figure 4: Impact of lirilumab on CD8+ T cells. A: Total peripheral CD8+ T cells were manually pregated and exported for t-SNE analysis. Consensus files of αIgG4+ CD8+ T cells were generated with fixed number cells for each treatment arm at each time point. Consensus files were then projected on t-SNE plots of total CD8+ T cells. B: CD69 expression by treatment arm and by time point of blood collection. C: Variations of T cell triggering receptors, immune checkpoints and activation markers expression between C1D8 and C4D1. Paired samples from patients included in 1.0 arm were analyzed using hierarchical clustering. For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. **P* < 0.05; ***P* < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study.

Figure 5 : impact of lirilumab on v δ 2+ y δ T cells. A: Total peripheral v δ 2+ y δ T cells were manually pregated and exported for t-SNE analysis. Consensus files of αIgG4+ vδ2+ γδT cells were generated with fixed number cells for each treatment arm at each time point. Consensus files were then projected on t-SNE plots of total vδ2+ γδT cells. B: DNAM-1 and Bcl-2 expression by treatment arm and by time point of blood collection. C1D1H0 were pre-gated on KIR+ NK cells. C1D8 to EOS were pre-gated on KIR+ cells for placebo arm. C1D8 to EOS were pre-gated on αIgG4+ NK cells for arms A and B. C: variations of absolute counts of αIgG4+ νδ2+ γδT cells during the cours of treatment. D: Bcl-2 expression at C1D8 according to LFS. E: Variations of Bcl-2 expression between C1D1H0 and C1D8 according to LFS (upper and middle panels). Time to relapse according to Bcl-2 variations between C1D1H0 and C1D8 (lower panel). For multiple comparisons, data were analyzed using a Kruskal-Wallis test followed by a Dunn's post test, and presented as interquartile ranges, median, and whiskers from minimum to maximum. Paired samples were analyzed using a Wilcoxon matched-pairs signed rank test. Comparison between two groups were performed using a Mann–Whitney *U* test. **P* < 0.05; ***P* < 0.01; ns, nonsignificant. C1D1H0: cycle 1 day 1 hour 0; C1D8: cycle 1 day 8; C4D1: cycle 4 day 1; C7D1: cycle 7 day 1; EOS: end of study; LFS: leukemia-free survival; PCB: placebo.

